Economic Impact of Potential CYP450 Pharmacokinetic Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioids

Joseph V. Pergolizzi, Sumedha A. Labhsetwar, R. Amy Puenpatom, Rami Ben-Joseph, Robert Ohsfeldt, Kent H. Summers

Research output: Contribution to journalArticle

Abstract

Chronic low back pain (cLBP) patients who take at least 1 CYP450-metabolized opioid analgesic agent concurrent with at least 1 other CYP450-metabolized medication experience a drug-drug exposure (DDE), which puts them at risk for a pharmacokinetic drug-drug interaction (PK DDI). This study compared utilization of healthcare resources and associated payments in cLBP patients with and without incident DDEs with the potential to cause PK DDIs. A retrospective database analysis examined the associated clinical events, healthcare utilization (measured in terms of claims for office visits, outpatient visits, emergency department visits, and hospitalization), and cost to the health plan, as defined as the sum of health plan payments for resources used. Patients were grouped into 2 cohorts by age (those under 65 and those 65years and over). In the 6months after exposure, total healthcare payments were significantly higher for DDE patients than those without DDEs (no-DDE), in both in the younger ($7,086, SD=$8,370) and $6,353, SD=$8,352, respectively, P

Original languageEnglish (US)
Pages (from-to)45-56
Number of pages12
JournalPain Practice
Volume12
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Low Back Pain
Drug Interactions
Opioid Analgesics
Pharmacokinetics
Economics
Pharmaceutical Preparations
Dichlorodiphenyl Dichloroethylene
Delivery of Health Care
Office Visits
Health Care Costs
Analgesics
Hospital Emergency Service
Hospitalization
Outpatients
Databases
Health

Keywords

  • Analgesics
  • Back pain
  • Low back pain
  • Lower back pain
  • Narcotics
  • Opioid
  • Opioid analgesics
  • Pharmacologic actions
  • Therapeutics

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Pergolizzi, J. V., Labhsetwar, S. A., Amy Puenpatom, R., Ben-Joseph, R., Ohsfeldt, R., & Summers, K. H. (2012). Economic Impact of Potential CYP450 Pharmacokinetic Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioids. Pain Practice, 12(1), 45-56. https://doi.org/10.1111/j.1533-2500.2011.00503.x

Economic Impact of Potential CYP450 Pharmacokinetic Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioids. / Pergolizzi, Joseph V.; Labhsetwar, Sumedha A.; Amy Puenpatom, R.; Ben-Joseph, Rami; Ohsfeldt, Robert; Summers, Kent H.

In: Pain Practice, Vol. 12, No. 1, 01.2012, p. 45-56.

Research output: Contribution to journalArticle

Pergolizzi, JV, Labhsetwar, SA, Amy Puenpatom, R, Ben-Joseph, R, Ohsfeldt, R & Summers, KH 2012, 'Economic Impact of Potential CYP450 Pharmacokinetic Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioids', Pain Practice, vol. 12, no. 1, pp. 45-56. https://doi.org/10.1111/j.1533-2500.2011.00503.x
Pergolizzi, Joseph V. ; Labhsetwar, Sumedha A. ; Amy Puenpatom, R. ; Ben-Joseph, Rami ; Ohsfeldt, Robert ; Summers, Kent H. / Economic Impact of Potential CYP450 Pharmacokinetic Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioids. In: Pain Practice. 2012 ; Vol. 12, No. 1. pp. 45-56.
@article{38f2e675f333487695cf544f82079c71,
title = "Economic Impact of Potential CYP450 Pharmacokinetic Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioids",
abstract = "Chronic low back pain (cLBP) patients who take at least 1 CYP450-metabolized opioid analgesic agent concurrent with at least 1 other CYP450-metabolized medication experience a drug-drug exposure (DDE), which puts them at risk for a pharmacokinetic drug-drug interaction (PK DDI). This study compared utilization of healthcare resources and associated payments in cLBP patients with and without incident DDEs with the potential to cause PK DDIs. A retrospective database analysis examined the associated clinical events, healthcare utilization (measured in terms of claims for office visits, outpatient visits, emergency department visits, and hospitalization), and cost to the health plan, as defined as the sum of health plan payments for resources used. Patients were grouped into 2 cohorts by age (those under 65 and those 65years and over). In the 6months after exposure, total healthcare payments were significantly higher for DDE patients than those without DDEs (no-DDE), in both in the younger ($7,086, SD=$8,370) and $6,353, SD=$8,352, respectively, P",
keywords = "Analgesics, Back pain, Low back pain, Lower back pain, Narcotics, Opioid, Opioid analgesics, Pharmacologic actions, Therapeutics",
author = "Pergolizzi, {Joseph V.} and Labhsetwar, {Sumedha A.} and {Amy Puenpatom}, R. and Rami Ben-Joseph and Robert Ohsfeldt and Summers, {Kent H.}",
year = "2012",
month = "1",
doi = "10.1111/j.1533-2500.2011.00503.x",
language = "English (US)",
volume = "12",
pages = "45--56",
journal = "Pain Practice",
issn = "1530-7085",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Economic Impact of Potential CYP450 Pharmacokinetic Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioids

AU - Pergolizzi, Joseph V.

AU - Labhsetwar, Sumedha A.

AU - Amy Puenpatom, R.

AU - Ben-Joseph, Rami

AU - Ohsfeldt, Robert

AU - Summers, Kent H.

PY - 2012/1

Y1 - 2012/1

N2 - Chronic low back pain (cLBP) patients who take at least 1 CYP450-metabolized opioid analgesic agent concurrent with at least 1 other CYP450-metabolized medication experience a drug-drug exposure (DDE), which puts them at risk for a pharmacokinetic drug-drug interaction (PK DDI). This study compared utilization of healthcare resources and associated payments in cLBP patients with and without incident DDEs with the potential to cause PK DDIs. A retrospective database analysis examined the associated clinical events, healthcare utilization (measured in terms of claims for office visits, outpatient visits, emergency department visits, and hospitalization), and cost to the health plan, as defined as the sum of health plan payments for resources used. Patients were grouped into 2 cohorts by age (those under 65 and those 65years and over). In the 6months after exposure, total healthcare payments were significantly higher for DDE patients than those without DDEs (no-DDE), in both in the younger ($7,086, SD=$8,370) and $6,353, SD=$8,352, respectively, P

AB - Chronic low back pain (cLBP) patients who take at least 1 CYP450-metabolized opioid analgesic agent concurrent with at least 1 other CYP450-metabolized medication experience a drug-drug exposure (DDE), which puts them at risk for a pharmacokinetic drug-drug interaction (PK DDI). This study compared utilization of healthcare resources and associated payments in cLBP patients with and without incident DDEs with the potential to cause PK DDIs. A retrospective database analysis examined the associated clinical events, healthcare utilization (measured in terms of claims for office visits, outpatient visits, emergency department visits, and hospitalization), and cost to the health plan, as defined as the sum of health plan payments for resources used. Patients were grouped into 2 cohorts by age (those under 65 and those 65years and over). In the 6months after exposure, total healthcare payments were significantly higher for DDE patients than those without DDEs (no-DDE), in both in the younger ($7,086, SD=$8,370) and $6,353, SD=$8,352, respectively, P

KW - Analgesics

KW - Back pain

KW - Low back pain

KW - Lower back pain

KW - Narcotics

KW - Opioid

KW - Opioid analgesics

KW - Pharmacologic actions

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84855728472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855728472&partnerID=8YFLogxK

U2 - 10.1111/j.1533-2500.2011.00503.x

DO - 10.1111/j.1533-2500.2011.00503.x

M3 - Article

VL - 12

SP - 45

EP - 56

JO - Pain Practice

JF - Pain Practice

SN - 1530-7085

IS - 1

ER -